Nucelis plans to put out first squalane product in 2015, with vitamin D2 commercialization in 2016

We recently spoke with Sean O'Connor, CEO and President of Nucelis, now a wholly owned affiliate of Cibus (see the January 9, 2014 LRMCJ), and got updates on the company's commercialization plans. Sean said Nucelis is planning to transfer its pilot plant squalane production process to a contract ...

This item has been archived in line with our efforts to keep our content relevant and up to date for our readership. For further assistance, please contact your Customer Success Manager or email ClientEngagementTeam@luxresearchinc.com. Thank you!

Related Research

New startup Arkeon Biotechnologies raises EUR 6.5 million to convert CO₂ into proteins

News Commentary | March 31, 2022

Arkeon Biotechnologies, an Austrian startup founded in 2021, has raised EUR 6.5 million seed funding from Synthesis Capital and ReGen Ventures to develop its CO2‑to‑protein technology, which uses microbial gas fermentation processes to convert industrial CO2 emissions into sustainable alternative ... Not part of subscription

Global Bioenergies

Company Profile | March 25, 2022

Uses genetically modified Escherichia coli to produce bioisobutene at a premium in gaseous form; can be used unmodified as an additive in gaseous fuel bottles or converted into isooctane, isododecane, butyl rubber, polyisobutene, methacrylic acid, or ethyl tertiary butyl ether (ETBE) Developed ... To read more, click here.

DMC

Company Profile | April 19, 2022

Uses dynamic metabolic control to optimize high‑margin microbial products including flavors and fragrances, nutraceuticals, natural products, active pharmaceutical ingredients, and amino acids Claims its technology is a quicker and more efficient than brute force methods employed by dominant ... Not part of subscription